logo
Childcare provider cancels meeting amid confusion for parents caught up in alleged sex offences saga

Childcare provider cancels meeting amid confusion for parents caught up in alleged sex offences saga

Parents say they are angry after a childcare giant that employed alleged child sex offender Joshua Dale Brown claimed police asked that a meeting with families be cancelled, amid frustration from other parents who have been asked to get children tested for sexually transmitted diseases a second time.
Warning: This story contains details of alleged child sex offences which may distress some audience members.
But Victoria Police have denied advising childcare operator Affinity Education to cancel the Thursday night meeting at the Papilio Early Learning Centre in Essendon.
In an email sent to parents on Thursday afternoon, and obtained by the ABC, Affinity said: "As the investigation is still open, we have been advised by the police that there is nothing further to share at this time and therefore the meeting has been postponed."
"We understand how distressing this is and that you may still have unanswered questions."
A parent at Papilio Essendon told the ABC they were desperately seeking more information from centre management.
"It's chaotic for sure," they said.
"At the moment we know as much as the general public and that's the source of frustration."
A police spokesperson told the ABC: "Victoria Police did not advise Papilio Essendon to not go ahead with the planned meeting."
"Victoria Police has given no instruction to impacted childcare centre operators regarding their meetings with families. That is up to centre operators to determine and organise as they see fit," they said.
Meanwhile, parents at other centres where Mr Brown worked are furious at what they say is a lack of clear communication from authorities, leaving them feeling they cannnot "trust the Health Department advice".
The department said on Wednesday its highest priority was the health and wellbeing of the children, as reports emerged that families had received conflicting screening advice, meaning their children might need to be tested twice.
Two families at Williamstown's Only About Children received texts recommending their children be tested for gonorrhoea and chlamydia on Tuesday, only to receive another message also recommending syphilis screening two days later, according to media reports.
"We acknowledge this is an extremely distressing time for everyone involved, and regret that this family faced additional stress and anxiety," the department said in response.
Another parent at the Williamstown centre told the ABC they proactively had their child tested for all three illnesses.
They said their child had been recommended for gonorrhoea and chlamydia screening, while others enrolled at the same centre at the same time were being told to also test for syphilis.
"A number of other families took matters into their own hands and did the same, and also tested for HIV and other diseases, because they realised they couldn't trust the health department advice," the parent said.
The parent criticised what they characterised as a "bungle" by the health department.
"They have had weeks and weeks of working with the police to get things right and yet they still stuffed it," they said.
"They clearly learned nothing from COVID."
Mr Brown, 26, of Point Cook, faces more than 70 charges including sexual penetration of a child under 12 and producing child abuse material relating to eight alleged victims at Creative Gardens Early Learning Centre in Point Cook between April 2022 and January 2023.
He also worked at several Affinity centres including Papilio in Essendon, which was his last-known employer before he was arrested in May.
Affinity did not comment when asked about the cancelled meeting.
According to information released by the Victorian government on Tuesday, Mr Brown worked at Papilio Early Learning in Essendon between February 17 and May 9 this year.
The government said he had also worked at the Only About Children in Williamstown between October 28, 2020, and March 30, 2021.
This week, Affinity said it was re-examining its records to see if Mr Brown worked for it on additional dates to those so far publicly disclosed, after the ABC approached the company with evidence he was at a different centre on a date not included on the government's list.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Scott Power: ASX health lifts to start FY26, Tetratherix ends IPO drought
Scott Power: ASX health lifts to start FY26, Tetratherix ends IPO drought

News.com.au

time5 hours ago

  • News.com.au

Scott Power: ASX health lifts to start FY26, Tetratherix ends IPO drought

ASX health up 1.6% over five days as Morgans' Scott Power says the mood is positive for start of FY26 Wound management house Tetratherix make its ASX debut and breaks an IPO drought for sector ProMedicus surges past $300 for first time following two new US customer contracts worth a total $190 million Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 27 years, gives his take on the ASX healthcare sector for the week and his 'Powerplay' stock pick. Morgans' senior healthcare analyst Scott Power has started FY26 in an optimistic mood, noting that despite the global geopolitical and economic uncertainties of recent months, the market broadly has been powering through and hitting new highs across many sectors. He noted healthcare was the laggard, with the S&P/ASX 200 Health Care Index falling 1.05% in June and down 6.64% YTD but said there was money flowing into the market more broadly. "If you look across the market there's multiple capital raisings going on across different sectors," he said. "That is suggesting people are feeling more confident and putting money to work." Wound management house Tetratherix (ASX:TTX) made its ASX debut on Monday breaking an IPO drought for the sector and trading up to 13% above their $2.88 a share offer price. Tetratherix is the first life sciences IPO since late November 2024, when cryogenics play Vitrafy Life Sciences (ASX:VFY) and nerve repair house ReNerve (ASX:RNV) listed on the same day. Barrenjoey Markets and Morgans Financial were joint lead managers and underwriters to the Tetratherix IPO. The S&P/ASX 200 Health Care index (ASX:XHJ) was up 1.6% for the past five days, while the benchmark S&P/ASX 200 (ASX:XJO) rose 0.6% for the past five days. "Over the past couple of months it has been pretty downbeat but it certainly feels a lot more upbeat, particularly since the end of the financial year and all the tax loss selling out of the way," Power said. ProMedicus surges past $300 on contract wins Health imaging stock ProMedicus (ASX:PME) surged ~10% on Thursday to rocket past $300 for the first time after announcing two new US customer contracts worth a total $190 million. The first win is a $170 million, 10-year contract with Colorado-based UCHealth, for the company's suite of image viewing and storage tools. The deal expands Promedicus into cardiology imaging, one of the adjacent 'ologies' the company had been targeting. UCHealth is a Colorado-based network of 14 hospitals, with affiliate clinics extending into Wyoming and Nebraska. Louisiana-based Franciscan Missionaries of Our Lady Health also renewed an existing contract for $20m, over five years. The deal renews a contract for the company's Visage 7 viewer, at a higher per-transaction fee. It also provides the merciful missionaries with Visage 7 Open Archive, which offers 'best-in-class interoperability'. The UCHealth contract is ProMedicus' largest deal to date and follows a $330m, 10-year agreement signed in November with Trinity Health, one of the largest not-for-profit healthcare systems in the US. "This company just goes from strength to strength and with the share price currently above $300 it has more than recovered from the wobbles it had in April when US President Donald Trump announced the tariffs," Power said. Morgans maintains a trim rating on ProMedicus and increased its 12-month target price from $250 to $280. "We view PME as one of the highest quality businesses on the ASX with high margins and long contracted revenue base, providing significant baseline earnings support," healthcare analyst Iain Wilkie wrote in a note to client. "We have a DCF valuation of A$280 p/s and with shares trading above this level, we advocate for active investors to TRIM overweight positions." Power's Powerplay – Micro X pivots to focus on medical applications Leader in cold cathode x-ray technology for health and security markets Micro-X (ASX:MX1) is Power's pick of the week. Power said the company had recently raised capital, added a strategic investor and realigned its business to focus on medical imaging, deprioritising security and defence. He said the realignment made sense and the business was funded to execute on the strategy. "It's early days in the realignment and customer receipts from imaging are still modest, although a major US hospital is evaluating the Rover+ mobile x-ray unit which could result in material sales over time," he said. Morgans has a speculative buy rating on Micro X and 12-month target price of 17 cents. Underperformers selling up assets Power said there were underperforming companies across the ASX healthcare sector, which were looking to, or have managed to, sell their primary assets. He said examples were Next Science (ASX:NXS) and MedAdvisor (ASX:MDR). Next Science has entered a binding asset purchase agreement to sell substantially all its assets for US$50m to Demetra, an Italian based healthcare company. The directors have unanimously recommended shareholders vote in favour of the proposed transaction. Assuming the transaction is completed at an EGM on August 14 and after repayment of debts and other costs, NXS will distribute remaining funds to shareholders estimated to be US$30m (~15 cents per share). MedAdvisor has entered into a binding share sale and purchase agreement to sell its ANZ business division and associated intellectual property to Jonas Software AUS Pty Ltd – part of multinational Constellation Software for $35m. "In both cases from a share price perspective they have significantly underperformed for a long time and the decision has been made, in my opinion correctly, to find a buyer," Power said. "Albeit, shareholders will have lost money but it's better to at least get something rather than let the value of the business deteriorate more. "I wouldn't be surprised if there are more companies which follow that path as across the life science sector there has been dozens of companies which have had massive share price underperformance." EMVision makes progress on key trials EMvision Medical Devices (ASX:EMV) announced this week five of the six sites were now enrolling and scanning patients in the pivotal validation trial for its first commercial device – the emu point-of-care bedside brain scanner for stroke diagnosis. EMVision said the site initiation visit and device training at the third US site for the pivotal trial – designed to support US Food and Drug Administration (FDA) de novo (new device) clearance for emu – at the Mount Sinai site in New York was a success, with recruitment underway. The sixth and final site, on the west coast of the US, for the pivotal trial is expected to be announced shortly. The trial has an estimated enrolment period of 6-12 months, followed by analysis and reporting of the clinical data. EMVision said in parallel it was also undertaking cost-effective strategy for continued device innovation, algorithm enhancement and data to support indication expansion to traumatic brain injury. Referred to as EMVision's Continuous Innovation Study the initiative has received ethics approval received to start scanning patients with suspected stroke or traumatic brain injury at Brisbane's Princess Alexandra Hospital and John Hunter Hospital in Newcastle shortly. "EMVision is making good progress," Power said. Neurizon signs global licensing deal with NYSE-listed Elanco Neurizon Therapeutics (ASX:NUZ) has entered an exclusive global licensing deal with New York Stock Exchange-listed Elanco Animal Health Incorporated and affiliates for monepantel, the active pharmaceutical ingredient in its lead drug NUZ-001. Neurizon said the licensing deal strengthen its strategic outlook for development, manufacturing and potential future commercialisation of NUZ-001, which is in development for the most common form of motor neurone disease (MND) called amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company said the licensing agreement also strengthens its regulatory position by providing ongoing access to essential animal safety and manufacturing data — both critical pillars for advancing clinical trials, securing potential regulatory approvals, and enabling global market entry. In a note to client Wilkie said Neurizon was a strong proposition in the rare disease space with significant near-term catalysts in a condensed timeframe and precedent for an accelerated approval pathway. "While considerable clinical risk remains, we view NUZ-001 as a drug with a sound scientific basis in ALS, strong safety profile, and promising hint of potential efficacy above existing treatments," he wrote. Morgans has a speculative buy rating on Neurizon and 12-month target price of 42 cents. The views, information, or opinions expressed in the interview in this article are solely those of the interviewee and do not represent the views of Stockhead. Stockhead has not provided, endorsed or otherwise assumed responsibility for any financial product advice contained in this article. At Stockhead, we tell it like it is. While EMVision and Neurizon are Stockhead advertisers, the companies did not sponsor this article.

Flu cases, hospitalisations on the rise as SA government urges for more vaccinations
Flu cases, hospitalisations on the rise as SA government urges for more vaccinations

ABC News

time8 hours ago

  • ABC News

Flu cases, hospitalisations on the rise as SA government urges for more vaccinations

Reported flu cases across South Australia have spiked 70 per cent this year, according to government data, prompting fears about the health system's capacity to cope with more hospital presentations. The state government released data on Friday showing there had been 10,569 reported flu cases so far in 2025, up from 6,212 at the same time last year. It comes after a total of 1,627 new flu cases were reported in the past week, which is almost the highest number of cases reported in any week for the past five years, according to the government. The number of people hospitalised due to the flu has also increased to 1,042 this year, compared to 673 at this point last year. Health Minister Chris Picton said the flu case spike was causing two problems: an increase in hospital presentations and more health workers taking sick leave. "We have seen a spike in hospitalisations and significantly more hospitalisations because of the flu than the same time last year," Mr Picton said. "And also, we've seen more absences in terms of many of those workplaces because the workers themselves have the flu." Mr Picton said workplace flu absences were affecting GPs, doctors, and aged care workers. He said there had "never been a more important time to make sure that you're vaccinated for flu". "That's why we're focusing our efforts particularly in terms of young kids, but also older people and people who have chronic health conditions." South Australia's take-up of the flu vaccine is the highest of any mainland states at 32.1 per cent of the population, according to the state government. That is higher than Victoria at 29.9 per cent, New South Wales at 26.8 per cent and Western Australia and Queensland at 25.8 per cent, the government said. The flu spike comes as the state's hospital system continues to struggle with demand. Ambulance ramping hours soared to their third-highest level on record in May, with patients spending 4,791 hours waiting outside public hospitals for treatment. The data, the most recent released by the state government, was taken before the onset of winter and the spike in flu cases Last year's winter saw ambulance ramping reach record levels, with the paramedic's union fearing 2025 will be even worse. Paul Ekkelboom, general secretary of the Ambulance Employees Association (AEA), said the flu figures were "alarming". "History tells us it's only going to get worse from here," he said, adding it was "only a month into winter". "It's placing a huge strain on our health system, every winter there is an increase in the demand and this includes flu cases." Mr Ekkelboom said "from all accounts" ramping hours were going up, adding that ambulance crews were dealing with fatigue and burnout. "We are concerned it's only a matter of time before this situation, where demand can't be met, results in negative patient outcomes," he said.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store